Company
Headquarters: Taichung, Taiwan
Employees: 19
CEO: Dr. Yung-Shun Wen Ph.D.
TW$20.64 Billion
TWD as of Jan. 1, 2026
US$658.9 Million
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Alar Pharmaceuticals Inc. operates as a drug development company. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which primarily include opioid use disorder, chronic pain, and major depressive disorder. The company is developing ALA-1000, which is in Phase II clinical trials for the treatment of opioid addiction; and ALA-1300 and ALA-2000, which is in pre-clinical stage for opioid use disorder; and ALA-3000, which is in pre-clinical stage for treating treatment-resistant depression. The company was founded in 2016 and is based in Taichung, Taiwan.
Alar Pharmaceuticals, Inc. has the following listings and related stock indices.
Stock: TWSE: 6785 wb_incandescent